Creyos Cognitive Assessments Featured in Two Studies at AAIC 2026

Creyos said its digital cognitive testing platform was featured in two AAIC 2026 posters, including a dementia screener validated in a clinical sample with 100% sensitivity (14/14 Alzheimer’s patients) and 86% specificity vs case-matched controls. It also highlighted R-FIRE research assessing how chronic bushfire smoke exposure in 1,800+ rural firefighters may affect brain health using Creyos alongside exposure surveys and biomarker sampling. Overall, the news is a positive scientific validation update, but it is unlikely to materially move markets without broader commercialization or regulatory milestones.

Analysis

This is more of a signal about where cognitive-care workflow could go than a near-term revenue event. The economic value only appears if digital screening becomes embedded in primary care, neurology, or employer/occupational health pathways; until then, posters and validation studies are not a monetization trigger. The most plausible public-market beneficiaries are downstream rather than the platform itself: diagnostics and Alzheimer’s treatment ecosystems (LLY, BIIB) gain if earlier identification expands the pool of patients who proceed to confirmatory testing and therapy, while hospitals/health systems could see modest referral uplift but also higher false-positive management burden.

The main second-order risk is that “better screening” creates cost and liability before it creates reimbursement. If specificity is not strong enough in larger, noisier populations, payers and health systems will push back, and adoption stalls at pilot level. Over 1-3 months, the stock reaction in adjacent names should fade unless there is a commercial contract, guideline mention, or CMS coverage path; over 6-18 months, the structural thesis only matters if the tool gets wired into EHR workflows and reimbursable care models. The contrarian point: the market may overestimate how quickly AI/digital cognitive tests convert into recurring enterprise spend, especially in an area where clinicians are already overloaded and a false-positive creates downstream costs.

For the named tickers, there is no obvious direct tradeable read-through; the safest stance is to treat this as a watch item rather than a catalyst. If you want expression, the cleanest public-market proxy is a very small, staged long bias in Alzheimer’s treatment beneficiaries on pullbacks only after evidence of real-world adoption, not on conference abstracts. Falsifier: no reimbursement, no guideline traction, or larger validation data showing materially worse specificity than the poster-level numbers imply.

Key Decisions for Investors

• No immediate position in CYH/TSTS/WWRL; the article has too little direct economic linkage and any price reaction should be faded unless a real commercial contract follows within 1-3 months.
• Set a watch on LLY and BIIB for 6-18 months: if digital screening gets guideline or reimbursement traction, earlier detection can enlarge the treatable pool; consider buying on weakness only after evidence of workflow integration, not on conference headlines.
• Monitor DGX and LH as downstream diagnostics proxies over the next 1-3 quarters; if cognitive screening starts moving from research to routine care, these names should show referral capture, but absence of reimbursement is the key falsifier.
• Use a ‘wait-for-proof’ framework: only act if management discloses payer coverage, EMR integration, or multi-site deployment; otherwise treat this as academic validation with limited tradable impact.
• If you want an options expression, prefer small call spreads in LLY/BIIB only after evidence of adoption emerges; avoid outright longs here because the downside is time decay against a catalyst that may never arrive.